Tumor mutational burden (TMB) is an emerging characteristic in cancer and has been associated with microsatellite instability, defective DNA replication/repair, and response to PD-1 and PD-L1 blockade immunotherapy. When estimating TMB, targeted panel sequencing is performed using a few hundred genes; however, a comparison of TMB results obtained with this platform and with whole exome sequencing (WES) has not been performed for various cancer types. In the present study, we compared TMB results using the above two platforms in 2,908 solid tumors that were obtained from Japanese patients. For next-generation sequencing, we used fresh-frozen tissue specimens. The Ion Proton System was employed to detect somatic mutations in the coding genome and to sequence an available cancer panel that targeted 409 genes. We then selected 2,040 samples with sufficient tumor cellularity for TMB analysis. In tumors with TMB-high (TMB ≥ 20 mutations/Mb), TMB derived from WES correlated well with the estimated TMB (eTMB) based on panel sequencing, whereas TMB in the remaining tumors showed a weak correlation. In particular, eTMB was overestimated in tumors with low-frequency mutations, resulting in the accumulation of EGFR mutations not being discriminated as a feature of lung cancer with low-frequency mutations. The eTMB in tumors harboring POLE mutations and microsatellite instability was not overestimated, suggesting that panel sequencing could accurately estimate TMB in tumors with high-frequency mutations such as hypermutator tumors. These results may provide helpful information for interpreting TMB results based on clinical sequencing using a targeted gene panel.
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ABSTRACT
Tumor mutational burden (TMB) is an emerging characteristic in cancer and has been associated with microsatellite instability, defective DNA replication/repair, and response to PD-1 and PD-L1 blockade immunotherapy. When estimating TMB, targeted panel sequencing is performed using a few hundred genes; however, a comparison of TMB results obtained with this platform and with whole exome sequencing (WES) has not been performed for various cancer types. In the present study, we compared TMB results using the above two platforms in 2,908 solid tumors that were obtained from Japanese patients. For next-generation sequencing, we used fresh-frozen tissue specimens. The Ion Proton System was employed to detect somatic mutations in the coding genome and to sequence an available cancer panel that targeted 409 genes. We then selected 2,040 samples with sufficient tumor cellularity for TMB analysis. In tumors with TMB-high (TMB ≥ 20 mutations/Mb), TMB derived from WES correlated well with the estimated TMB (eTMB) based on panel sequencing, whereas TMB in the remaining tumors showed a weak correlation. In particular, eTMB was overestimated in tumors with low-frequency mutations, resulting in the accumulation of EGFR mutations not being discriminated as a feature of lung cancer with low-frequency mutations. The eTMB in tumors harboring POLE mutations and microsatellite instability was not overestimated, suggesting that panel sequencing could accurately estimate TMB in tumors with high-frequency mutations such as hypermutator tumors. These results may provide helpful information for interpreting TMB results based on clinical sequencing using a targeted gene panel.
The development of next-generation sequencing has led to the use of tumor mutational burden (TMB) as a hallmark of cancer. An increase in TMB in the human cancer genome is known to be attributable to endogenous factors and environmental damage (25) . Variations in DNA replication/repair-related genes generate massive somatic mutations (1, 4, 5, 23, 26) . In contrast, exogenous stimuli, including UV radiation (3), tobacco smoke (1), and chemicals (13, 14, 20) , induce the accumulation of mutations in genes. TMB represents a potential biomarker for inferring the process of tumorigenesis.
control for next-generation sequencing.
DNA isolation. For DNA analysis, tumors and normal tissues were immediately frozen in liquid nitrogen prior to DNA extraction. DNA was extracted from tissue and peripheral blood samples using a QIAamp DNA blood Mini Kit (Qiagen, Venlo, Netherland).
The purified DNA was quantified using a NanoDrop and a Qubit 2.0 Fluorometer (Thermo Fisher Scientific, Waltham, MA, USA).
Next-generation sequencing. The exome library for WES was constructed using an Ion AmpliSeq Exome RDY Kit (Thermo Fisher Scientific) in accordance with manufacturer's recommended protocol (21, 22, 32 PD-1 and PD-L1 (also known as PDCD1 and CD274, respectively) blockade immunotherapies are highly effective in only some patients (12, 34 ). An accurate predictor for a companion diagnosis is thus considered necessary to derive benefit from these therapies. A recent clinical trial revealed that TMB was associated more with response rate than with PD-L1 immunohistochemistry (28) . The measurement of TMB is valuable not only to surmise the cancer characteristics but also to predict the clinical response to immunotherapy. In a number of reports, TMB was calculated from somatic mutation counts in the coding genome using whole exome sequencing (WES). Two research groups that collaborated with Foundation Medicine suggested the possibility that TMB can be estimated from a few hundred genes (6, 15) . TMB estimation using a targeted gene panel provides a cost-effective and clinically available tool. However, these comparisons between WES and panel sequencing were performed in small-scale samples.
In the current study, to clarify whether panel sequencing can accurately surmise TMB as well as WES, we evaluated the TMB results from over 2,000 Japanese patients with solid tumors using WES and a targeted gene panel. To exclude the influence of tumor content on mutation frequency, samples with a lower tumor cellularity were not included. We employed an available targeted gene panel that included 409 genes. The TMBs calculated using the two platforms were highly correlated. However, the estimated TMB based on panel sequencing was significantly overestimated in samples harboring lower TMB levels, suggesting that the available targeted gene panel could accurately estimate TMB in tumors with high-frequency mutations. These findings may be helpful to interpret TMB results based on clinical sequencing using a targeted gene panel.
MATERIALS AND METHODS
Patients and specimens. Informed consent was obtained from all patients, and the Institutional Review Board of Shizuoka Cancer Center approved all aspects of this study (Authorization Number: 25-33).
All experiments using clinical samples were performed in accordance with the approved guidelines. Each tumor and its surrounding normal tissue (≥ 100 mg) were dissected from surgical specimens immediately after resection of the lesion. The tumor sample was visually assessed by a clinical pathologist in our hospital to contain a ≥ 50% tumor content. In addition, peripheral blood was collected as a COSMIC (10), ClinVar (16), dbSNP (31), UniProt (36) , and DrugBank (38) .
Statistical analysis. The significance of the association of the mutations between the two groups was analyzed using Fisher's exact test. PD-L1 gene expression data derived from the microarray were normalized, and a significant difference of expression was calculated using Welch's t-test. For frequency of mutation and tumor cellularity determined using PurBayes (17) , the assumptions of normality and the equality of two variances were tested using the Shapiro-Wilk test and F-test, respectively. Welch's t-test was performed in the assumed normal distribution. For comparison of samples assuming a non-normal distribution, a Mann-Whitney-Wilcoxon or BrunnerMunzel test (also known as the generalized Wilcoxon test) was performed depending on the assumption of the F-test. In this study, p < 0.05 was considered significant.
RESULTS
Extraction of samples with sufficient tumor cellularity
We performed WES and CCP using 2,908 solid tumor samples from 2,836 patients with cancer. All samples collected at our single hospital were composed of multiple tissues, among which colorectal, lung, and stomach cancers occupied 63% of the whole content (Fig. S1 , each sample is listed in Table S1 , URL: http://10.6.186.1/researchinstitute/ wp-content/uploads/sites/10/2018/04/Hatakeyama_ BiomedRes2018_Supplementary_TableS1.xlsx). To exclude samples with a low tumor content, tumor cellularity was calculated using PurBayes (17) , and the low values (< 0.25) were then grouped as low tumor cellularity (Fig. 1A) . In this study, 3 non-mutated tumors were omitted from the TMB analysis. The top 3 samples (colorectal, lung, and stomach) occupied 63% of the remaining contents (Fig. 1B) . The frequency of low tumor cellularity in samples taken from the thymus and pancreas exceeded 60% for each tumor type (Fig. 1C) . We further investigated the relationship of tumor cellularity with TMB for WES and CCP, finding that the TMB of samples with low tumor cellularity (< 0.25) was lower than the eTMB from CCP (Fig. 2) . To confirm the distribution of mutation frequency, we compared TMB results for each tumor type. The median TMB was 3.1 mutations/Mb, and 6.6% of cases had 20 or more mutations/Mb (Fig. 1D) . Consistent with the previous reports that included mainly Caucasian subjects (1, 6), highly mutated samples were frequently obwith a Custom Hotspot file that specifies somatic and pathogenic mutations registered in COSMIC and ClinVar, respectively. The list of identified mutations was processed by in-house scripts to remove false-positive calls, including sequencer-derived errors. Mutations fulfilling at least one of the following criteria were discarded as false-positive: [1] quality score < 60, [2] depth of coverage < 20, [3] variant read observed in one strand only, [4] clipped sequence length < 100 (avg_clipped_length < 100), [5] variant located on either sequence end (avg_pos_as_ fraction < 0.05), and [6] mutation matches one on an in-house false-positive list. Parameters specified in criteria [4] and [5] were calculated by bam-readcount with option "−q 1" (ver. 0.8.0) (https://github.com/ genome/bam-readcount). For CCP, tumor CCP sequence reads were compared with blood WES reads to identify somatic mutations. First, variant calling for tumor samples was performed using Torrent Variant Caller (TVC) (ver. 4.4, Thermo Fisher Scientific), and then, blood data were analyzed by TVC with custom hotspot, which specifies all detected mutations in a tumor sample to determine whether those mutations were observed in the blood sample. Because a different variant caller and higher depth were used compared to those used for WES, the following criteria were used to identify unreliable mutations: [1] quality score < 50, [2] depth of coverage < 20, or [3] mutation matches one on an in-house false-positive list. Our WES analysis focused on single/multiple nucleotide variations located in an exon and splice site, and the mutation frequency on the genome was then evaluated using an effective length (≥ 20 × coverage in each sample) for the TMB calculation. CCP analysis targeted exonic regions and splice sites of 409 genes (~1.6 Mb) and calculated TMB from the mutation count and effective length as the estimated TMB (eTMB). Arbitrary somatic mutations were manually inspected using the Integrative Genomics Viewer (27) to avoid sequencer and amplicon-derived errors. Briefly, frequently mutated sites and variations that were barely detected in both tumor and blood samples were extracted from the sequencing data. These somatic mutation candidates containing multiple nucleotide variations (~1,000 sites) were validated by Sanger sequencing to exclude false-positive variations. The mutations that were not detected in Sanger sequencing were included in the in-house false-positive list. The effects of mutations were predicted using SnpEff (8) .
RefSeq was adopted as the source of curated and annotated sequences. Somatic mutations in the exome were annotated using the following databases: based on a few hundred genes was defined as eTMB (see Materials and Methods). To clarify whether eTMB can be used to infer TMB calculated from the coding genome, we compared TMB and eTMB derived from WES and CCP, respectively. The values calculated using the two platforms were highly correlated (r = 0.966; Fig. 3A ). TMB levels were divided into three groups based on a previous report (11): low (≤ 5 mutations/Mb), high (≥ 20 mutations/ Mb), and intermediate (the margin between these intervals). In CCP, no mutation was detected in 7 samples that were almost classified as TMB-low in WES (86%, 6/7), whereas eTMB based on CCP was overestimated (Fig. 3B ). This tendency was particularly observed in TMB-low in WES (median TMB ratio, 2.6). Overall, although the mutation analysis using served in tumors derived from the colon, stomach, lung, and uterus; however, the frequencies for tumors derived from lung and uterus (6.0% and 29.4%, respectively) were different from those reported previously (12.3% and 15.7%, respectively) (6). This indicated that the TMB pattern in these Japanese patients with cancer was similar to pattern reported for Caucasian patients.
Comparison of TMB between WES and a targeted gene panel
TMB based on WES was calculated using somatic mutations in the coding genome (~34.8 Mb), whereas that based on CCP was estimated from exonic regions in 409 genes (~1.6 Mb) sharing part of another targeted gene panel (Fig. S2) . In this study, TMB (2.95 Mb) (22) were compared as a panel with similar and large exonic region size. The variability in low-frequency mutations tended to increase as the target region decreased (Fig. 4B and Fig. S3 ), suggesting that the accuracy of eTMB depended on the exonic region size. Including a higher number of target genes in panel sequencing may improve the accuracy of eTMB for tumors with low-frequency mutations.
Relationship between TMB-high signatures and TMB
Several tumors with higher TMB levels have been associated with the response to PD-L1 blockade immunotherapy, and POLE mutation or microsatellite instability (MSI) is often observed in these samples despite an indirect relationship between TMB and PD-L1 (9, 18, 19, 37) . To clarify the POLE or MSI status in tumors classified with eTMB based on CCP, we extracted Signature.6 (MSI) and Signature.10 (POLE) based on 30 mutational signatures (1) assessed using deconstructSigs (29) . Tumors harboring predominant Signature.6 and 10 (> 0.5) are defined as MSI and POLE, respectively, and the remaining samples are defined as others. In the tumors with MSI or POLE status, 96% of samples (48/50) were classified into the TMB-high level in both WES and CCP (Fig. 5) . This result suggests that eTMB based on CCP was not overestimated in TMB-high samples harboring MSI or POLE mutations.
DISCUSSION
Excess contamination with non-tumor cells reduces the detection sensitivity of somatic mutations (35) . We estimated tumor cellularity using PurBayse (17) in 2,908 fresh-frozen samples derived from Japanese patients with cancer. In the pancreas and thymus, over 60% of samples had low tumor cellularity (< 0.25). Tumor samples collected from the pancreas for use in next-generation sequencing are often insufficient without microdissection (2, 24, 39) . Although tumor cellularity is considered to influence TMB calculated from WES, we found that eTMB based on CCP was stable regardless of tumor celluthe targeted gene panel was strongly correlated with that using WES, eTMB overestimated TMB in tumors harboring low-frequency mutations.
Impact of the overestimation of eTMB
To evaluate the influence of the overestimation on the TMB classification of the tumor types, we compared the fraction of TMB intervals between WES and CCP. The eTMB based on CCP classified 68% of samples as TMB-intermediate (Fig. 3C) . Notably, the distribution of tumors derived from the lung and colon was altered in the TMB-intermediate group based on CCP (Fig. 3D) . EGFR mutations in lung cancer have been detected at a higher rate in samples with lower TMB (33) . Here, EGFR mutations were significantly accumulated in the TMB-low interval based on WES but not on CCP (Table 1) . These results indicated that the overestimation that occurred with eTMB influenced the TMB classification of a portion of tumors harboring low-frequency mutations.
Characteristics of eTMB derived from WES
CCP was more deeply sequenced in the limited exonic region than WES. For the frequency of somatic mutations, CCP exceeded WES targeting a large coding genome. These findings raise the possibility that the CCP platform or exonic region size for sequencing may influence the overestimation of eTMB. To clarify this influence, we extracted mutations in 409 genes that were also in the CCP from WES, and then, eTMB was calculated using the corresponding exonic region size including splice sites (1.32 Mb). Although the eTMB values between CCP and CCP genes from WES were highly correlated (r = 0.970), eTMB based on CCP was overestimated (Fig. 4A ). This result suggested that the CCP platform was related to the overestimation of TMB. To further investigate the effect of exonic region size, we extracted other gene sets from WES for calculation of eTMB. In this calculation, 318 FoundationOne genes (0.85 Mb) and 139 guidance genes (0.42 Mb), some of which were also among the CCP genes, were used (see Fig. S2 ). Additionally, 467 MSK-IMPACT genes (1.20 Mb) (7) and 1,130 cancer-related genes n.s., not significant sequencing can be used to estimate mutational burden in a tumor as well as capture-based next-generation sequencing.
Simulations of targeted gene panel sequencing using archived formalin-fixed paraffin-embedded clinical cancer specimens have shown that the percentage deviation from the actual TMB increases in the lower levels of TMB (6) . Consistent with these results, the sampling variation of eTMB based on CCP was notably increased in TMB-low samples in the present study. We found that CCP with 409 genes overestimated TMB in the TMB-low interval. Furthermore, EGFR mutations that were observed in lower TMB samples were indistinguishable from eTMB based on CCP, suggesting that the known feature of tumors harboring low-frequency mutations (33) was not detected by the panel sequencing. For typical larity compared with that based on WES. Estimation of TMB using a targeted gene panel may be of value for samples containing a low tumor content.
In a previous report, some differences were confirmed between amplicon-and capture-based WES (30). Our analysis was performed using a semiconductor DNA sequencer based on amplicon sequencing against a coding genome (WES) or exonic regions in 409 genes (CCP). Chalmers et al. showed that TMB estimated from targeted gene panel sequencing (~1.1 Mb) agreed well with whole exome measures of mutation burden based on capture sequencing (Illumina HiSeq platform) (6) . Consistent with this report, eTMB based on CCP was strongly correlated with TMB calculated from WES. This finding indicated that a targeted gene panel using a semiconductor DNA sequencer based on amplicon 
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TMB levels excluding TMB-high values, panel sequencing targeting a few hundred genes may produce results that disagree with whole exome measures of mutation burden despite presenting a strong TMBwide correlation, confounding predictions of cancer characteristics.
In conclusion, the present study analyzed the TMB characteristics of 2,908 Japanese patients with cancer (2,040 samples finally selected as sufficient tumor cellularity cases) and found a similar observed mutation frequency as reported in previous studies with mainly Caucasian patients. TMB calculated from WES correlated well with the eTMB based on CCP that included 409 genes. However, the eTMB in samples with lower TMB levels was overestimated compared with the mutation frequency calculated from WES, suggesting that panel sequencing could accurately estimate TMB in tumors with high-frequency mutations. These results may provide valuable information to improve diagnostic accuracy using TMB based on clinical sequencing using a targeted gene panel.
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We thank the members of the Shizuoka Cancer Center Hospital and Research Institute for their support (29)) were defined as MSI and POLE, respectively, and the remaining samples were defined as others. Grey lines indicate 5 and 20 mutations/Mb. In TMB from WES, ≤ 5 and ≥ 20 mutations/Mb were defined as TMB-low and TMB-high, respectively, and the margin between these intervals was defined as TMB-intermediate.
